+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Proliferation Kit Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 121 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5529287
UP TO OFF until Mar 31st 2024

The Cell Proliferation Kit (CPK) Market is expected to register a CAGR of 7.5% during the forecast period. The major factors attributing to the growth of the market are rising volume of patients diagnosed with cancer, tumors and ongoing R&D activities across the globe. As per World health Organization report, cancer is a leading cause of death worldwide and estimated that nearly 9.6 million deaths in 2018. Also, lung cancer was identified as the most common cancer leading to death with 1.76 million deaths in 2018. Thus, growing prevalence of these diseases resulted in earlier assessment of viable cell-count, metabolic activity for effective treatment fuels the market growth. Furthermore, rise in government initiatives to control the healthcare burden, and growing healthcare awareness among are likely boost the Cell Proliferation Kit market.

Key Market Trends

Colorimetry Sub-segment is Expected to Hold a Major Market Share in the Cell Proliferation Kit Market

Colorimetry holds a significant market share in Cell Proliferation Kit market over the forecast period. The dominance is owing to increased adoption as measuring markers of cell activity. Huge demand for the method is due to their cost effectiveness, easier retrieval of high-throughput data, and key role in assessment of therapeutic efficacy. This method is widely employed determining various cellular activity such as DNA synthesis, metabolic activity, ATP production, the number of cells present etc., Various types of colorimetric assays like WST-1, WST-8, XTT, MTT, and others are available specific to tests. Thus, above mentioned factors are expected to fuel the growth of the segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the cell proliferation kit market. The dominance is due to growing number of new cancer cases like melanoma, urothelial carcinoma, lung cancer, and others each year in the region. Also, the presence of huge population of baby boomers leads to huge volume of elderly people who are at the risk of cancers. According to the estimates published by the American Cancer Society for the year 2020, lung cancer is the second most common cancer leading to 135,720 deaths in both men and women. Also, as per Thyroid Cancer Survivors Association, thyroid cancer affects nearly 52,890 new cases in the United States in 2020, which increased from 52,070 cases in the year 2019. Thus, growing cancer cases leads to increased demand for determining the growth rate of cellular population driving the growth of the market. Furthermore, ongoing research activities in oncology by key pharma and biotech companies necessitates the use of these kits to determine the therapeutic efficiency of drugs. Therefore, due to above mentioned factors expected to boost the cell proliferation kit market in the region to a large extent during the forecast period.

Competitive Landscape

The cell proliferation kit market is moderately competitive and consists of a several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Merck KGaA, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Becton, Dickinson and Company, and Agilent Technologies Inc (BioTek Instruments Inc).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Technological Advancements in Cell-based Methodologies
4.2.2 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
4.2.3 Increasing Application in Drug Screening
4.3 Market Restraints
4.3.1 Lack of Skilled Personnel to Operate these Technologies
4.3.2 High Maintenance and Operational Costs
4.3.3 Lesser Sensitive Results with Smaller Samples of Cells
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 Assay Type
5.1.1 DNA Synthesis Cell Proliferation Assay
5.1.2 Metabolic Activity Cell Proliferation Assay
5.1.3 Antigen Associated Cell Proliferation Assay
5.2 Method
5.2.1 Colorimetry
5.2.2 Fluorescence
5.2.3 Others
5.3 End-user
5.3.1 Pharma & Biotech Companies
5.3.2 Academic & Research Institutes
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc
6.1.2 Merck KGaA
6.1.3 Bio-Rad Laboratories Inc
6.1.4 Becton, Dickinson and Company
6.1.5 Agilent Technologies Inc (BioTek Instruments Inc)
6.1.6 GE Healthcare
6.1.7 Perkin Elmer Inc
6.1.8 Biological Industry
6.1.9 Biotium
6.1.10 Mindray Medical International Limited